Larger and longer studies are required to confirm the effectiveness of combined SGLT1/SGLT2 inhibition in reducing MI and stroke in patients with type 2 diabetes and elucidate the mechanisms associated with this finding. This evidence concerns the gene SLC5A1 and type 2 diabetes mellitus.